Summarized by Masters of Longevity from Longevity Technology.
A concise news article previewing clinical trial biomarker and eye‑movement findings for a novel oral protein‑degrading therapy in Parkinson’s disease.
Key Takeaways
- ARV-102, an oral PROTAC, reached the brain and reduced cerebrospinal fluid LRRK2 and related biomarkers in patients.
- In 24 Parkinson's patients dosed 20–80 mg for 28 days, higher ARV-102 doses correlated with greater saccadic hypometria improvement.
- Reductions in LRRK2 were associated with lowered neuroinflammation markers and increased synaptic integrity markers in CSF.
